Peptide radiopharmaceuticals for diagnosis and therapy

Radiolabelled peptides are an emerging class of radiopharmaceuticals that share chemical and biological properties. From the chemical point of view they have a poly-amino acid structure varying from 3 to more that 200 amino acids, and they are labelled with different isotopes directly or by a linker...

Full description

Saved in:
Bibliographic Details
Published in:European journal of nuclear medicine 2001-10, Vol.28 (10), p.1555-1565
Main Authors: SIGNORE, A, ANNOVAZZI, A, CHIANELLI, M, CORSETTI, F, VAN DE WIELE, C, WATHERHOUSE, R. N, SCOPINARO, F
Format: Article
Language:English
Subjects:
Arteriosclerosis - diagnostic imaging
Arteriosclerosis - radiotherapy
Biological and medical sciences
Contrast media. Radiopharmaceuticals
Humans
Infection - diagnostic imaging
Infection - radiotherapy
Inflammation - diagnostic imaging
Inflammation - radiotherapy
Medical sciences
Miscellaneous
Neoplasms - diagnostic imaging
Neoplasms - radiotherapy
Nervous System Diseases - diagnostic imaging
Nervous System Diseases - radiotherapy
Peptides - therapeutic use
Pharmacology. Drug treatments
Radionuclide Imaging
Radiopharmaceuticals - therapeutic use
Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)
Thrombosis - diagnostic imaging
Thrombosis - radiotherapy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Radiolabelled peptides are an emerging class of radiopharmaceuticals that share chemical and biological properties. From the chemical point of view they have a poly-amino acid structure varying from 3 to more that 200 amino acids, and they are labelled with different isotopes directly or by a linker. Biologically, they bind to specific cell membrane receptors, thus providing in vivo histopathological information for diagnostic purposes, therapy follow-up or targeted radiotherapy. This paper reviews most of the radiolabelled peptides that have been tested in animals and humans in the fields of oncology, neurology, cardiology, inflammation/infection, atherosclerosis and thrombosis. A new classification is also proposed for peptides targeting tumour cells based on the biological function of target receptors. These tailored radiopharmaceuticals are the basis of the new era of "molecular nuclear medicine".
ISSN:0340-6997
DOI:10.1007/s002590100583